The short answer: KLOW is GLOW plus one extra peptide. GLOW is usually sold as GHK-Cu, BPC-157 and TB-500. KLOW adds KPV.
Both are market names, not drugs, so no formula is guaranteed. Neither blend appears to have been tested in people. And the October HHS compounding policy doesn't reach them: it's limited to one active ingredient per product, and GHK-Cu isn't on its list of six.
Status as of November 6, 2026: neither KLOW nor GLOW is an FDA-approved product, and none of the four ingredients is an approved drug. The HHS enforcement policy published October 30 is non-binding and open for comment through November 13. Nothing below is medical advice or a how-to.
Key takeaways
The only labeled difference is KPV, a three-amino-acid peptide. FDA found no human exposure data for it by any route.
A search of PubMed and ClinicalTrials.gov on November 6 found no human study of either blend.
Human evidence by ingredient: GHK-Cu has small skin studies, BPC-157 has five small studies, TB-500 and KPV have none that FDA could find.
The HHS policy covers six peptides, one per product. GHK-Cu isn't one of them, so both blends fall outside it twice.
One testing database doesn't score blends on dose at all, so a "pass" on a blend doesn't confirm the amounts.
Want the short version of what's actually approved, legal and tested? Get the free BHN cheat sheet.
KLOW vs GLOW: what's the difference?
One ingredient, KPV. Everything else on a typical label is shared.
GLOW | KLOW | |
|---|---|---|
GHK-Cu | Yes | Yes |
BPC-157 | Yes | Yes |
TB-500 | Yes | Yes |
KPV | No | Yes |
Standard formula | None | None |
Human trial of the blend | None found | None found |
Covered by the HHS policy | No | No |
Sources: Superpower, reviewed by an MD, updated Sept 28, 2026, Peptide Dossier. The last row is covered below.
What peptides are in KLOW?
Usually four: GHK-Cu, BPC-157, TB-500 and KPV. That comes from how sellers label it and how independent guides describe it. No regulator has defined it.
The name means nothing fixed outside that pattern. FDA's review of KPV, for example, describes compounded products pairing KPV with BPC-157, TB-500 and other substances, including one sold as a "regenerative combo" (FDA briefing document, July 2026). Same idea, different recipe, no KLOW label.
What is GLOW peptide?
GLOW is a label for a three-peptide blend: GHK-Cu, BPC-157 and TB-500. Peptide Dossier calls it "a marketing name, not a standardized finished medicine" (Peptide Dossier).
The commonly advertised split is 5:1:1, with GHK-Cu as the big share, then BPC-157 and TB-500. That makes GHK-Cu about 71% of the labeled weight. So the ingredient with no published human injection study is most of the vial.
Is there a standard KLOW or GLOW formula?
No. "The name is a market label, so doses, ratios, and purity vary by seller" (Superpower, 2026). The same guide says no regulator, pharmacopeia or clinical trial defines either one.
Where composition can vary:
The ratio. 5:1:1 is a common label for GLOW, not a rule. "Other labels may differ" (Peptide Dossier).
The form of each peptide. FDA says TB-500 has been sold as "multiple salts, and derivatives" under the same name (FDA briefing document, July 2026).
The name on the vial. The co-founder of a drug-testing company told TIME: "Or it'll say Glow, but it's actually Klow, or vice versa" (TIME, Feb 24, 2026).
What's the human evidence for each ingredient?
Thin for two, absent for two. None of it was done on a blend.
Ingredient | Human evidence | What else exists |
|---|---|---|
GHK-Cu | Small skin studies, mostly creams. No published human injection trial | Animal studies. A 2026 review called it "promising but unproven" |
BPC-157 | Five small studies found by FDA. None is a controlled trial in an injury | Large animal literature, mostly from one group |
TB-500 | None. FDA found no articles in which it was given to people | Very little on the fragment itself. Trials of full-length thymosin beta-4 are a different molecule |
KPV | None. FDA found no clinical studies or human exposure data by any route | Cell studies and mouse models |
Sources: Pharmaceutics, Aug 2026, FDA briefing documents on BPC-157, TB-500 and KPV, July 2026.
KPV is the one thing you'd be adding by choosing KLOW, so it deserves a closer look. It's made of lysine, proline and valine. The often-cited paper found it reduced inflammatory signaling in cells and colitis in two mouse models (Gastroenterology, 2008). FDA's conclusion on people: "potential safety risks associated with the use of KPV in humans are unknown" (FDA, July 2026).
The other three have their own posts: GHK-Cu cream vs injection and BPC-157 vs TB-500. If your question is about the sting, that's why GHK-Cu burns.
Has KLOW or GLOW been tested in people?
Not that I can find. On November 6, I searched PubMed and ClinicalTrials.gov for these names and for the ingredients together. PubMed returned no study of either blend, only general review articles. The registry showed no trial giving people any of these combinations.
The closest evidence covers only two of the ingredients:
One rat study. In 32 rats with repaired Achilles tendons, BPC-157 plus TB-500 "did not confer additional benefits compared to either agent alone" (Jt Dis Relat Surg, July 2026).
Four people in a chart review. They got BPC-157 plus thymosin beta-4, the full protein. Three reported relief. There was no comparison group (Altern Ther Health Med, 2021).
One FDA adverse event report. A 40-year-old woman using a BPC-157 and TB-500 product developed darkened skin and gums, and it came back when she used it again. FDA wrote that "because the product contained two peptides it is not possible to assess" whether BPC-157 was involved (FDA, July 2026).
That last line is the core problem. With four peptides in one vial, a bad reaction has four suspects, and a good result has no explanation.
There's a chemistry question too. The August GHK-Cu review warns that amino acids and other ingredients can "redistribute copper" away from the peptide (Pharmaceutics, 2026). It wasn't looking at blends, and a PubMed search found nothing on GHK-Cu's stability alongside these peptides. So nobody can say what happens to the copper in a shared vial.
Does the HHS peptide policy cover KLOW or GLOW?
No. The policy covers six peptides: BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. One of its 10 conditions reads: "The compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A" (HHS policy, Oct 2026). API means active ingredient.
Run the blends through that:
Check | GLOW | KLOW |
|---|---|---|
Single active ingredient? | No, three | No, four |
Every ingredient on the list of six? | No, GHK-Cu isn't | No, GHK-Cu isn't |
Every ingredient in a covered form? | No, GHK-Cu has none | No. KPV is covered only as topical or oral, and these blends are sold as injectables |
GHK-Cu's absence is the bigger point, because it's most of the vial. It wasn't part of the July panel vote that the six came out of. FDA says it will consult its compounding committee on GHK-Cu before the end of February 2027 (FDA). Its injectable nomination was withdrawn, and FDA's safety page still cites "limited data in humans" for injectable GHK-Cu (FDA).
Three limits on the policy itself:
It isn't approval. The notice calls it a draft and an interim policy, and says it "is not binding on HHS or the public" (Federal Register, Oct 30, 2026).
It's for pharmacies and physicians. It covers state-licensed pharmacies, federal facilities and licensed physicians. HHS says it wants to "discourage" use of peptides labeled research use only (HHS policy, Oct 2026).
It can still change. Comments run through November 13, and HHS says to check its site for the most current version.
The full breakdown is in the HHS peptide pass, and each peptide's status is on the compounding status tracker. KPV, BPC-157 and TB-500 each got an 8-6 vote with one abstention in July, against FDA staff's advice (DLA Piper, July 2026). More on that in the FDA panel vote.
Get the GHK-Cu panel date and any change to the HHS policy when they land. Join the BHN newsletter.
What's actually in a KLOW or GLOW vial?
You can't tell from the name. At least 20% of unapproved peptides tested by BTLabs since October 2025 were mislabeled, TIME reported in February, and that figure isn't specific to blends (TIME, 2026).
Blends are also harder to check. Finnrick's public database showed 23 KLOW tests (14 pass, 5 fail, 4 incomplete) and 4 GLOW tests (1 pass, 1 fail, 2 incomplete) on November 6. But its method says "Blends are not scored on dose deviation under any standard" (Finnrick). So a pass there speaks to identity and purity, not to whether the amounts match the label.
If you're looking at a COA for a blend, it needs to identify each peptide and its amount, for that lot. One overall purity number doesn't do that. See how to read a peptide COA and how to test peptides for purity.
KLOW or GLOW: which is better?
Nobody knows. No trial has compared them, or tested either one.
"KLOW is better because it adds KPV" assumes a mouse and cell finding carries over to people, inside a four-peptide mix. Nothing has tested that. The only time two of these ingredients were compared directly against their combination, in rats, the combination added nothing.
If you compete in a tested sport, both blends contain BPC-157 and TB-500, and both are banned at all times.
If you've seen a blend tested peptide by peptide, reply and tell me what the lab reported and whether it matched the label. Nobody has published that for these blends. I'll update this post when FDA dates the GHK-Cu meeting or HHS changes the policy.
KLOW vs GLOW FAQ
Is KLOW the same as GLOW?
No. KLOW is usually the GLOW blend plus KPV. Because neither name has a standard formula, a label is the seller's claim, not a guarantee.
Is KLOW FDA approved?
No. It isn't an approved product, and none of its four ingredients is an approved drug. The HHS policy isn't an approval either, and it doesn't cover blends.
Can a compounding pharmacy make KLOW under the HHS policy?
Not within the policy. It requires a single active ingredient from the list of six, and GHK-Cu isn't on that list. KPV is covered only in topical and oral forms.
Is GHK-Cu on the HHS peptide list?
No. The six are BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. FDA plans to consult its compounding committee on GHK-Cu before the end of February 2027.
What does KPV add to KLOW?
On the label, a fourth peptide. In the evidence, cell and mouse findings on inflammation and no human data. FDA says its risks in people are unknown.
Are there human studies on the GLOW peptide blend?
None that I could find in PubMed or ClinicalTrials.gov as of November 6, 2026. The closest evidence is a rat study of two of the ingredients and a four-person chart review.
Want the one-page version of what's approved, what's legal and what's actually been tested? Get the free BHN cheat sheet.